Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19.
Journal
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
10
09
2020
accepted:
30
09
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
30
12
2020
Statut:
ppublish
Résumé
This commentary addresses the state of the evidence on tobacco products, nicotine, and COVID-19. The evidence of the effects of smoking on respiratory infections and the immune system in general are examined and the current understanding of tobacco products and risk for SARS-CoV-2 infection and the course of COVID-19 is addressed.
Identifiants
pubmed: 33320258
pii: 6035093
doi: 10.1093/ntr/ntaa187
pmc: PMC7953960
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S93-S95Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.
Références
Lancet Respir Med. 2020 Sep;8(9):831
pubmed: 32805203
Dev Cell. 2020 Jun 8;53(5):514-529.e3
pubmed: 32425701
PLoS One. 2019 Jul 18;14(7):e0220204
pubmed: 31318967
Nicotine Tob Res. 2020 Aug 24;22(9):1669-1670
pubmed: 32383751
J Inflamm (Lond). 2020 Jun 10;17:21
pubmed: 32528233
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Adolesc Health. 2020 Oct;67(4):519-523
pubmed: 32798097
J Infect. 2019 Nov;79(5):401-406
pubmed: 31465780
Epidemiology. 2019 May;30(3):405-417
pubmed: 30789425
Addiction. 2020 Oct 2;:
pubmed: 33007104
C R Biol. 2020 Jun 05;343(1):33-39
pubmed: 32720486
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628